Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BRII-835 (VIR-2218)
BRII-835 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Participants will receive BRII-835 (VIR-2218) for 32 weeks |
| Cohort B | EXPERIMENTAL | Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40 |
| Cohort C | EXPERIMENTAL | Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40 |
| Name | Type | Description |
|---|---|---|
| BRII-835 (VIR-2218) | DRUG | BRII-835 (VIR-2218) will be given by subcutaneous injection |
| BRII-179 (VBI-2601) with IFN-α | BIOLOGICAL | BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection |
| BRII-179 (VBI-2601) | BIOLOGICAL | BRII-179 (VBI-2601) will be administered by intramuscular injection |
Inclusion Criteria: * Male or female aged 18 - 60 * Body mass index ≥ 18 kg/m\^2 and ≤ 32 kg/m\^2 * Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for...
BRII-835 is an investigational small molecule being developed for the treatment of chronic hepatitis B virus (HBV) infection. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied as part of a combination therapy approach to address chronic HBV infection.
BRII-835 targets the hepatitis B virus. As a small molecule designed to act against the virus itself, it is being investigated for its potential role in treating chronic hepatitis B infection. The drug is being evaluated in combination with other therapies to improve treatment outcomes for patients with this condition.
BRII-835 is being developed by Vir Biotechnology, Inc., a company traded on the stock exchange under the ticker symbol VIR. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for the treatment of chronic hepatitis B virus infection.
BRII-835 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities for commercial use. The drug is being studied in clinical trials to assess its safety and efficacy in patients with chronic hepatitis B virus infection.
BRII-835 has been studied in one completed Phase 2 clinical trial with the identifier NCT04749368. This trial investigated the safety and efficacy of BRII-835 in combination with BRII-179 for treating chronic hepatitis B virus infection. The study enrolled 91 participants across multiple countries including Australia, China, New Zealand, Singapore, South Korea, and Thailand.
Yes, BRII-835 is also known as VIR-2218. The drug is being developed by Vir Biotechnology, Inc. under the ticker symbol VIR. It is an investigational small molecule in Phase 2 clinical development for the treatment of chronic hepatitis B virus infection.